Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a balanced process controlled by pro- and anti-angiogenic molecules of which the regulation is not fully understood. Besides classical gene regulation, miRNAs have emerged as post-transcriptional regulators of angiogenesis. Furthermore, epigenetic changes caused by histone-modifying enzymes were shown to modulate angiogenesis as well. However, a possible interplay between miRNAs and histone-modulating enzymes during angiogenesis has not been described. Here we show that VEGF-mediated down-regulation of miR-101 caused pro-angiogenic effects. We found that the pro-angiogenic effects are partly mediated through reduced repression by miR-101 of the histone-methyltransferase EZH2, a member of the Polycomb group family, thereby increasing methylation of histone H3 at lysine 27 and transcriptome alterations. In vitro, the sprouting and migratory properties of primary endothelial cell cultures were reduced by inhibiting EZH2 through up-regulation of miR-101, siRNA-mediated knockdown of EZH2, or treatment with 3-Deazaneplanocin-A (DZNep), a small molecule inhibitor of EZH2 methyltransferase activity. In addition, we found that systemic DZNep administration reduced the number of blood vessels in a subcutaneous glioblastoma mouse model, without showing adverse toxicities. Altogether, by identifying a pro-angiogenic VEGF/miR-101/EZH2 axis in endothelial cells we provide evidence for a functional link between growth factor-mediated signaling, post-transcriptional silencing, and histone-methylation in the angiogenesis process. Inhibition of EZH2 may prove therapeutic in diseases in which aberrant vascularization plays a role.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
miRBase: microRNA sequences, targets and gene nomenclature
Griffiths-Jones, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj112 · Cited by 3,950
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“and VEGFR2 thereby causing endothelial cell survival, proliferation, and sprouting [7].”
BackgroundThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 2×
“EZH2-regulated genes indicated that EZH2 can act as a bona fide oncogene that stimulates an ‘active’ cell status by trimethylating lysine 27 of histone H3 [26,40–46].”
Background
Cited by
Items 101–119 of 119
Epigenetics and microRNAs in Cancer
Wise, P. M., Challagundla, K. B., & Fabbri, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_16 · Cited by 2
Casieri, V., Agostini, S., & Lionetti, V. (2014) · Current Angiogenesis · doi:10.2174/2211552802666140721184942 · Cited by 2
MicroRNA and Cardiovascular Disorders with a Focus on Angiogenesis
Cavarretta, E., Frati, G., & Condorelli, G. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5857-9_25 · Cited by 1
Franceschetti, T., & Delany, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-820719-2.00019-3 · Cited by 3
Floris, I. (2014) · UnissResearch (Università degli Studi di Sassari)
THE CONTRIBUTION OF INFLAMMATORY PATHWAY SIGNALING AND MICRORNA CHANGES TO COLON CANCER PROGRESSION
Onyeagucha, B. C. (2013) · UA Campus Repository (The University of Arizona) · Cited by 1
Role of MicroRNAs in Cancer Epigenetics
Challagundla, K. B., Wise, P. M., & Fabbri, M. (2013) · Springer eBooks · doi:10.1007/978-94-007-6612-9_2
Novel biosensors for preclinical brain tumor analysis
Niers, J. M. (2011) · Pure Amsterdam UMC
Self-citationMOLECULAR ASPECTS OF ENDOTHELIAL CELL FUNCTION AND HYPOXIA-DEPENDENT TUMOR ANGIOGENESIS
Kucharzewska, P. (2011) · Lund University Publications (Lund University)
Nakahara, O., Takamori, H., Sakamoto, Y., Tanaka, H., Chikamoto, A., Horino, K., Beppu, T., Honda, Y., Iyama, K., & Baba, H. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-3971
Targeting of Epigenetic Modifier EZH2 in Oropharyngeal Squamous Cell Carcinomas
Lindsay, C. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3cn6zf0h
Pharmacoepigenetics of EZH2 Inhibitors
Lindsay, C., Kostiuk, M. A., & Biron, V. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00009-7
Epigenetics and MicroRNAs in Cancer
Wise, P. M., Challagundla, K. B., & Fabbri, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_21
Epigenetic Regulation of miRNAs in Cancer
Ramasamy, D., Kodous, A. S., Mani, S., Rao, A. K. D. M., & Balakrishnan, A. (2026) · Advances in biochemistry in health and disease · doi:10.1007/978-3-032-08824-6_4
Oktar, P. A., Babadag, S., Güneş, M. Y., Aydoğdu, G. Ö., & Ezer, Ü. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102513
DZNep : A Methyltransferase Modulator for Disease Mitigation
Garg, S., & Miousse, I. R. (2026) · Environmental and Molecular Mutagenesis · doi:10.1002/em.70071
Fetal programming under hyperglycemic stress: the vascular system at risk
Xavier, F. E. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00390.2026
Hou, J., Chen, J., Chen, Y., Luo, Z., Yuan, S., 邓呈亮, & 肖顺娥 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1957976
Leclerc, A., Latrous, N., Lecot, A., Faisant, M., Emery, É., & Levallet, G. (2026) · Research Square · doi:10.21203/rs.3.rs-10119287/v1
Metadata
- Authors
- Smits, M., Mir, S. E., Nilsson, R. J. A., van der Stoop, P. M., Niers, J. M., Marquez, V. E., Cloos, J., Breakefield, X. O., Krichevsky, A. M., Noske, D. P., Tannous, B. A., & Würdinger, T.
- Affiliations
- Cancer Center Amsterdam (NL)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-28
- Volume
- 6
- Issue
- 1
- Pages
- e16282
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3030563
- OpenAlex
- W2025121278
- Cited by
- 118
- References
- 52
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 15 · 2019: 7 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 19 · 2013: 8 · 2012: 12
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- American Brain Tumor Association
- Vrije Universiteit Amsterdam
- KWF Kankerbestrijding
- National Cancer Institute (P01CA069246, CA069246, P50CA086355, CA 86355)
- National Institute of Neurological Disorders and Stroke (R01NS064983)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Plant Molecular Biology Research
- Keywords
- miR-101, EZH2, angiogenesis, endothelial cells, VEGF signaling, histone H3 lysine 27 methylation, Polycomb group proteins, microRNA regulation, DZNep, glioblastoma, post-transcriptional gene silencing, histone methylation, vascularization
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Cells, Cultured, DNA-Binding Proteins, Histones, Humans, Methylation, Transcription Factors, Down-Regulation, Neovascularization, Physiologic, MicroRNAs, Vascular Endothelial Growth Factor A, Angiogenic Proteins, Endothelial Cells, Mice, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.